Revlimid lenalidomide: Additional Phase III data

Additional data from the double-blind, international Phase III IFM 2005 02 trial in 614 patients showed that 17 patients treated with Revlimid as maintenance therapy following autologous stem cell transplantation developed secondary malignancies compared to 3 patients receiving placebo. Data were presented at the American Society of Hematology meeting in Orlando. The trial was sponsored by the Intergroupe Francophone du Myelome and University Hospital of Toulouse. ...